Spotting Red Flags: Understanding how Biotech Top Line Press Releases about FDA Meetings Can "Trick" Investors.Ticker(s): IBB
A former FDA regulatory official who has worked at the agency and interacted with pharmaceutical companies previously.
This conversation will pull real life examples of press releases and delays to illustrate issues.
72Days Left to Join Project
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.